By interrupting the inflammatory cycle driven by NLRP3 activation, CP-456,773 could indirectly slow nephrolithiasis progression, making it a valuable therapeutic candidate for inflammation-associated kidney stone disease. Here, NLRP3 is linked to nephrolithiasis.